A Variant of Uncertain Significance in a Woman With Triple-Negative Breast Cancer and a Strong Family History
A 41-year-old woman was diagnosed with triple-negative breast cancer at age 38 (T2N0; treated with lumpectomy, adjuvant chemotherapy, and radiation). Her mother was diagnosed with high-grade serous ovarian cancer at 58 and died at 61. A maternal aunt had breast cancer at 45 and is alive at 70. At diagnosis the patient had a 30-gene germline panel: no pathogenic variants, but an ATM missense change reported as a variant of uncertain significance. She has completed treatment and now requests bilateral mastectomy and risk-reducing salpingo-oophorectomy, and asks whether her 15-year-old daughter should be tested.
1. How do you counsel her about the variant of uncertain significance and her surgical request?
Read the worked answer
A VUS is not a result you act on. By definition the classification means the evidence is insufficient to say whether the variant causes disease. Roughly 90% of VUS reclassify as benign over time. Bilateral mastectomy or salpingo-oophorectomy performed because of a VUS exposes her to surgical risk, irreversible hormonal consequences, and body-image effects for no established benefit. That is the answer to her surgical request - and it must be delivered as a clear "no, and here is why," not as a hedge that leaves her thinking surgery is pending a recheck.
But her family history is doing real work, and it should not be dismissed. Mother with high-grade serous ovarian cancer at 58, aunt with breast cancer at 45, and the patient herself with triple-negative breast cancer at 38. That pattern is not explained away by a negative panel - it warrants:
- Testing the affected relative. Her mother has died, but archived tumor tissue may allow germline or somatic testing (BRCA1/2 and broader HRD genes). A maternal aunt is living and affected - offer her testing. If a pathogenic variant is found in an affected relative, the patient can be retested specifically for it, and the VUS question becomes moot.
- Genetics re-referral for variant reclassification every 2–3 years; classifications change.
- Consider whether the panel was adequate - large rearrangements, and genes added since the original panel, may not have been covered.
The honest framing: "We are not recommending surgery based on this variant. We are recommending that we keep working on your family's genetics, because your history is significant even though this particular result is not actionable."
2. What surveillance would you recommend for her breasts and ovaries, and how do you justify it?
Read the worked answer
Breasts:
- Annual mammography of the remaining breast tissue - she had lumpectomy plus radiation, so surveillance covers the treated breast and the contralateral breast.
- Add annual breast MRI given her young age at diagnosis and the family history. This is not strictly mandated by a VUS, but a first-degree relative with ovarian cancer and a young-onset breast cancer in the family justify enhanced screening, and MRI has better sensitivity in dense, previously irradiated breast tissue. Alternating mammogram and MRI every 6 months is a practical schedule.
- Discuss that enhanced screening is a risk-management choice, not an established guideline-directed intervention for a VUS - she should understand the difference.
Ovaries:
- There is no proven screening test for ovarian cancer. Transvaginal ultrasound and CA-125 have not been shown to reduce mortality and produce false positives that lead to surgery. Do not order them as "surveillance."
- Risk-reducing salpingo-oophorectomy is not indicated on the basis of a VUS. It may still be discussed on the basis of the family history - a mother with high-grade serous ovarian cancer at 58 is meaningful - but as a shared decision with gynecologic oncology, timed after completion of childbearing (typically around age 40–45 in this scenario), and framed as a family-history-driven choice rather than a genetic-test-driven one. Document that distinction.
- If she elects surgery, she needs counseling about surgical menopause and hormone therapy considerations.
Why the asymmetry: breast screening has demonstrated mortality benefit; ovarian screening has not. Recommending the former and refusing to order the latter is internally consistent, not arbitrary.
3. How do you answer the question about testing her 15-year-old daughter?
Read the worked answer
No - and the reason is layered, which is why it is worth explaining carefully rather than just refusing.
- There is no pathogenic variant to test for. Cascade testing only works when a known pathogenic variant has been identified in the family. A VUS cannot be used for predictive testing, and testing a relative for it would generate another ambiguous result with no clinical utility - or worse, a result that gets over-interpreted.
- Even if a pathogenic BRCA variant were later found, testing minors for adult-onset hereditary cancer predisposition is not recommended absent a childhood-actionable finding. There is no pediatric intervention for BRCA-related risk, and testing removes the child's own future choice about knowing her status.
- What the daughter needs now is not a blood test. She needs age-appropriate information, sun protection and HPV vaccination, a conversation about what breast awareness means in her twenties, and - later - a referral for genetics at age 18+ if she wants it, or earlier if a pathogenic variant is identified in the family.
Reframe the concern. The mother is really asking, "Is my daughter at risk?" That is answerable without a test: her daughter's risk depends on whether a pathogenic variant is eventually found in the family. This is why pursuing testing of the affected aunt and reanalysis of the patient's panel matters - it converts an unanswerable question into an answerable one.
Also address the family communication piece. The patient should be encouraged to tell adult relatives about the family history so they can seek their own assessment; the clinic can provide a family letter. That is the highest-yield action available today.